ZFP36 stabilizes RIP1 via degradation of XIAP and cIAP2 thereby promoting ripoptosome assembly. by Selmi, Tommaso et al.
Selmi et al. BMC Cancer  (2015) 15:357 
DOI 10.1186/s12885-015-1388-5RESEARCH ARTICLE Open AccessZFP36 stabilizes RIP1 via degradation of XIAP and
cIAP2 thereby promoting ripoptosome assembly
Tommaso Selmi1, Claudia Alecci1, Miriam dell’ Aquila1, Lucia Montorsi1, Andrea Martello1, Filippo Guizzetti1,
Nicola Volpi1, Sandra Parenti1, Sergio Ferrari1, Paolo Salomoni2, Alexis Grande1 and Tommaso Zanocco-Marani1*Abstract
Background: ZFP36 is an mRNA binding protein that exerts anti-tumor activity in glioblastoma by triggering cell
death, associated to an increase in the stability of the kinase RIP1.
Methods: We used cell death assays, size exclusion chromatography, Co-Immunoprecipitation, shRNA lentivectors
and glioma neural stem cells to determine the effects of ZFP36 on the assembly of a death complex containing
RIP1 and on the induction of necroptosis.
Results: Here we demonstrate that ZFP36 promotes the assembly of the death complex called Ripoptosome and
induces RIP1-dependent death. This involves the depletion of the ubiquitine ligases cIAP2 and XIAP and leads to
the association of RIP1 to caspase-8 and FADD. Moreover, we show that ZFP36 controls RIP1 levels in glioma neural
stem cell lines.
Conclusions: We provide a molecular mechanism for the tumor suppressor role of ZFP36, and the first evidence
for Ripoptosome assembly following ZFP36 expression. These findings suggest that ZFP36 plays an important role
in RIP1-dependent cell death in conditions where IAPs are depleted.
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ZFP36 belongs to the TIS11/TTP protein family, a class
of mRNA binding proteins carrying a conserved zinc fin-
ger domain, which binds to AU-rich elements in the 3′
UTR of mRNAs. ZFP36 triggers mRNA decay and or in-
hibition of translation of its targets, resulting in negative
regulation of gene expression [1]. A growing body of lit-
erature demonstrates the ability of ZFP36 to negatively
regulate mRNAs coding for oncogenes in different cellu-
lar contexts thereby exerting anti-tumor activities [2-5].
Interestingly, it has been shown that ZFP36 sensitizes
transformed cell lines to TNF alpha-induced cell death
[6] and we have recently described the role of ZFP36 in
promoting necroptosis in glioma cell lines [4].
Cells die by activating many forms of programmed cell
death, such as apoptosis and necroptosis, which are
characterized by the assembly of intracellular complexes* Correspondence: zanocco@unimore.it
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unless otherwise stated.that execute death sentences [7]. The Ripoptosome is a
recently described death-inducing complex, whose as-
sembly is triggered in responsive cancer cell lines by
Etoposide or SMAC-mimetics [8, 9]. Once assembled,
this complex signals both apoptotic and necroptotic cell
death, independently of the activation of the TNF-
receptor superfamily [8]. The Ripoptosome contains the
core components RIP1, caspase-8 and FADD. It has
been suggested that the stability of this complex is regu-
lated by the E3 ubiquitine ligases XIAP, cIAP1 and
cIAP2, which act by marking the core components for
proteasome-mediated degradation [8]. Etoposide and In-
terferons are used to induce cell death dependent on
RIP1 [8, 10] however, only few details are known regard-
ing the intracellular mediators of the necroptotic effects
of these drugs [11]. We previously demonstrated that
ZFP36 acts as tumor suppressor in glioma cell lines by
inducing necroptotic cell death and we speculated that
RIP1 stabilization could be responsible for the execution
of this death program [4]. Here we show that ZFP36 sta-
bilizes RIP1, promotes the assembly of the Ripoptosomehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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lecular event underlining this process is the depletion of
the IAP proteins XIAP and cIAP2, which we and others
[4, 12] previously described as a target of ZFP36-
mediated mRNA decay. Finally we demonstrate that loss
of ZFP36 in glioma cancer stem cells leads to the down-
regulation of RIP1, thus reinforcing the molecular link
between ZFP36 and RIP1.
Methods
Cell cultures
Human embryonic kidney (HEK) 293 T cells were ob-
tained from ATCC and cultured in IMDM medium
(Euroclone) supplemented with 10% heat-inactivated
fetal bovine serum (Biowhittaker), 1 mM L-glutamine
and penicillin/streptomycin (100 μg/ml) (Euroclone). As
described by Pollard et al. [13], G144 human glioma
neural stem (GNS) cell lines were maintained onto lam-
inin (10 mg/ml, Sigma) coated dishes in expansion media
(RHA-B media from Stem Cell Technologies) supple-
mented with 20 ng/mL of EGF (recombinant mouse,
PeproTech 315–09 20 ng/ml) and 20 ng/mL bFGF (recom-
binant human, PeproTech100-18B, 20 ng/ml). Medium
was changed every 2 days, and cells were split 1:2 to 1:3
once culture became confluent.
Chemicals and treatments
Where indicated, HEK293T were treated with 100 μM
Etoposide (Invitrogen), 20 μM Z-VAD-FMK (Invitro-
gen), 50 μM Necrostatin-1 (Enzo Life Sciences) and
DMSO (Sigma) served was administered as vehicle.
Expression constructs
Full-length ZFP36 was cloned in the pCDNA3.1 vector
(Invitrogen) as already described in reference 4. The
pCI-IRES-HA-XIAP (Δ3′UTR XIAP) allows the expres-
sion of the XIAP coding sequence driven by its own
IRES and was a gift from Dr Salomoni.
Cell death assays
HEK293T were transfected using the Transit 2020 Re-
agent (Mirus Bio LLC) according to manufacturer’s in-
struction. In the co-transfection experiments, the same
amount in μg for each plasmid was added to the trans-
fection mix. 48 hours after transfection, cell death was
assessed by Propidium Iodide (PI) or Annexin V/Propi-
dium Idodide staining (AV/PI). For PI staining, cells
were cultured in the presence of 0.5 μg/mL PI (BD Phar-
MingenTM) for 15 minutes and imaged using a Leica
5515015 inverted microscope. AnnexinV/PI positivity
was assessed by BD PharMingenTM kit (cat. Number
556547) at the cytofluorimeter (Coulter Epics XL MCL,
Beckman Coulter Inc.). Trypan Blue positivity was used
to count dead cells in Neubauer Chambers. HEK293cells were gently detached from plates after short
incubations (60″) in 1X Trypsin-EDTA solution (Life
Technologies). Error bars represent mean and SEM
calculated on a set of three to four independent expe-
riments (*p < 0.05; **p < 0.01).
Chromatographic separation
Cellular lysates were fractionated by gel-permeation size-
exclusion chromatography on Sepharose 6B (Sigma-Al-
drich, fractionation range for globular proteins 1 × 104 ÷
4 × 106) column of 90 cm high and 1 cm of diameter. The
column was eluted with 5% w/v sucrose, 0.1% w/v
CHAPS, 20 mM HEPES, 5 mM DTT, and 50 mM NaCl,
buffered at pH 7.0. Column flow was 1 mL/5 min and
fractions volume was set at 2 mL. The column was cali-
brated with protein standards and blue dextran (Sigma-
Aldrich). After elution, fractions were freeze-dried and
further analyzed.
Co-Immunoprecipitations, western blots and antibodies
For the Ripoptosome immunoprecipitation, cells were
transfected with the ZFP36 expression vector or with the
empty vector. 24 hours following transfection, Z-VAD-
FMK and, where indicated, also Etoposide were added for
further 24 hours. Cells were then lysed in 30 mM Tris
(pH 7.4), 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 10%
glycerol, 0.2% NP-40, 1 mM sodium deoxycholate, 1 mM
sodium orthovanadate and Complete Protease Inhibition
Cocktail (Roche), and caspase-8 was immunoprecipitated
with 2 mg of caspase-8 (1C12) monoclonal antibody (Cell
Signaling, 9746) coupled to protein G agarose (KPL). The
CO-IP negative control was immunoprecipitated using
non-specific mouse IgG (Santa Cruz Biotechnology). Im-
munoprecipitates where resuspended in 2x Laemmli Buf-
fer without SDS and heated at 100° for 5′ prior to loading
onto SDS-polyacrylamide gels. Membranes were probed
against RIP1 (BD Transduction Laboratories, #610458),
caspase-8 (1C12) (Cell Signaling, 9746) and (BD Trans-
duction Laboratories, #610399). IgG-HRP secondary anti-
bodies were from Santa Cruz Biotechnology (sc-2031) and
the Mouse TrueBlot (ebioscience).
Other antibodies used were: ZFP36 (Abcam, ab124024),
TTP (H-120) (Santa Cruz biotecnology, sc-8458), XIAP
(Cell Signaling, #2042), cIAP2 (H-85) sc-7944 (Santa Cruz
Biotchnology), PARP-1 (F-2) sc-8007 (Santa Cruz biotec-
nology), MLKL M6697 Sigma-Aldrich), VINCULIN clone
V284 (Merck Millipore). Expression of actin was analyzed
with a mouse anti-human pan-actin MoAb (Sigma-
Aldrich) to normalize protein samples.
Lentivectors
To knockdown ZFP36 expression in human glioma
neural stem cells, we used the commercially available
pGIPZ-lentiviral shRNAmir vectors containing a hairpin
Figure 1 (See legend on next page.)
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Figure 1 ZFP36 controls RIP1 stability by depleting IAPs and promotes RIP1-dependent cell death. A). Transfection of HEK293T cells with a ZFP36
construct (ZFP36) correlates with the depletion of cIAP2 and with an increase in the stability of RIP1 at 48 hours. HEK293T cells transfected with a XIAP
construct depleted of its own 3′UTR (Δ3′UTR XIAP) show a reduction in the levels of RIP1, even in the presence of ZFP36 (ZFP36 +Δ3′UTR XIAP). B)
Image J software was used to normalize the levels of RIP1 over beta-ACTIN. C) Real Time PCR showing RIP1 mRNA levels following ZFP36 and Δ3′UTR
XIAP over-expression. D) Both the transfection of ZFP36 and the treatment with Etoposide induce the formation of MLKL homo-oligomers and a decrease
of MLKL monomers. E.V. cells were incubated with DMSO as this is the vehicle for Nec-1 administration. Non-reducing conditions were applied in order to
preserve intact oligomers of MLKL. E) HEK293T transfected with the ZFP36 construct (ZFP36) show increased positivity to Propidium Iodide staining (P.I.),
which is reduced in the presence of the Δ3′UTR XIAP construct (ZFP36+ Δ3′UTR XIAP). F) Percentage of P.I. positive cells obtained from 5 fields for each
condition from experiment 1C. G-H) 48 hours treatment with 50 μM Necrostatin-1 inhibits ZFP36-dependent cell death (ZFP36 Nec-1) if compared to
DMSO treated cells (ZFP36 vehicle), as assessed by cytofluorimetric analysis of Annexin V / P.I. or positivity to Trypan blue. The graphs in this figure
represent the mean and SEM calculated on a set of three to four independent experiments (*p < 0.05; **p < 0.01).
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pin sequence was as follows: CGACTTTATTTATTCT
AATATTACATCTGTGGCTTCACTAATATTAGAATA
AATAAAGTCG.
The shRNA-containing lentiviral vector (Open Biosys-
tems) was cotransfected with lentiviral packaging con-
structs into HEK293T cells to produce shRNA-carrying
lentivirus particles. Supernatants were collected at 48 h
after transfection and viral particles were concentrated
using PEG (System Biosciences). GNS cells were trans-
duced (MOI = 10) for 1 h and subsequently supple-
mented with fresh media. After expansion, cells were
sorted (MoFlo cell sorter, Beckman Coulter Inc.) based
on GFP expression values, obtaining two homogeneous
populations expressing either the (pGIPZ) scrambled
vector, or pGIPZ shRNA ZFP36 (shZFP36). To perform
over-expression experiments, the coding sequence of
ZFP36 [4] was cloned in the pRRLSIN.cPPT.PGK-
GFP.WPRE vector. The procedure for producing the
lentiviral particles and infecting the cells was the same
as described for the pGIPZ vectors. ZFP36 expressing
cells were used for experiments 24 to 48 hours after
infection.
Results
ZFP36-mediated RIP1 stabilization depends on IAPs
degradation and correlates with increased cell death
Experimental evidences demonstrate that ZFP36 triggers
the degradation of XIAP and cIAP2 mRNAs, which carry
AU-rich elements in their 3′UTR [4, 12]. Figure 1A shows
that in HEK293T cells, that endogenously express cIAP2
and lower levels of XIAP, ZFP36 over-expression deter-
mines the down-regulation of cIAP2, which correlates with
an increase in RIP1 (Figure 1A, B). This confirms that loss
of IAPs activity can stabilize RIP1 [8, 14] and suggests that
ZFP36 might regulate RIP1 through IAPs degradation. Ac-
cordingly, the observed increase in RIP1 was abolished by
the co-transfection of a XIAP construct lacking the 3′
UTR, which cannot be degraded by ZFP36 (Δ3′UTR
XIAP) (Figure 1A, B). This was further confirmed when a
more physiological induction of ZFP36 was achieved by
means of lentiviral infection (results are shown inadditional file 1 A, B) in the supplementary material sec-
tion. In order to verify whether the increase of RIP1 de-
pends on protein stabilization rather than on increased
mRNA expression, we analyzed by Real Time PCR the
levels of RIP1 mRNA. No statistically significant changes
in RIP1 mRNA levels were detected (Figure 1C), suggest-
ing that RIP1 protein is stabilized following ZFP36
expression.
Mixed lineage kinase domain-like protein (MLKL) is
currently the main confirmed effector of RIP kinases-
dependent necropotsis [15]. Upon activation of necrop-
tosis, the monomeric form of MLKL decreases, owing to
the formation of homo-oligomers that relocate to the
plasma and intracellular membranes, where they com-
promise membrane integrity, resulting in cell death [15].
As a result of ZFP36 overexpression, the monomeric
form of MLKL decreases while an increase of the homo-
oligomeric form is observed (Figure 1D).
As cells overexpressing ZFP36 show an increase in
RIP1 and in the oligomerized MLKL, we checked the
permeability of these cells to propidium iodide. As
shown in Figure 1E-F, where graph F recaps the per-
centages observed in 1E, cells overexpressing ZFP36
are more permeable to propidium iodide than cells ex-
pressing ZFP36 and the Δ3′UTR XIAP, suggesting that
they are less sensitive to ZFP36-induced cell death
(ZFP36 +Δ3′UTR XIAP). To confirm that ZFP36-induced
cell death is dependent on RIP1 we inhibited this kinase
with its inhibitor Necrostatin-1 (Nec-1). Figure 1G-H
shows that Nec-1 partly restrains ZFP36-dependent cell
death in HEK293T cells, thus confirming that ZFP36 trig-
gers RIP1-dependent cell death. Collectively, the data
shown in Figure 1 demonstrate that the negative regulation
exerted by ZFP36 over the XIAP and cIAP2 E3 ubiquitine
ligases is a key mechanism controlling the stability of RIP1
and the sensitivity to necroptotic cell death.
ZFP36-mediated RIP1 stabilization leads to Ripoptosome
assembly
Based on these observations, we hypothesized that the in-
creased availability of RIP1 could result in its loading into
the 2MDa Ripoptosome. To assess this, we first confirmed
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only in the presence of ZFP36 (Figure 2A) and then we
co-immunoprecipitated the Ripoptosome components
(Figure 2B-D). Our results demonstrate that the binding
of RIP1 to caspase-8 is promoted by ZFP36 overexpres-
sion (Figure 2B, C), and that similar results are observed
in response to Etoposide (Eto.), a Ripoptosome-stabilizing
drug that acts through depleting IAPs [8]. When comparing
empty vector (E.V.) to ZFP36-transfected cells (ZFP36), theFigure 2 ZFP36 promotes RIP1 assembly in a high molecular weight com
empty vector/ZFP36 transfection, HEK293T cells were further treated for 2
caspases’ activity and facilitate the recovery of the Ripoptosome, as descri
was added in the co-immunoprecipitation experiments depicted in figure
and 20 μM Z-VAD-FMK. A) 2 milligrams of lysates from either empty vecto
column and fractions were eluted at defined timing and then loaded on p
ZFP36, RIP1 was detected in higher molecular weight fractions (54–71), w
was loaded for each sample series (C+). Molecular weight markers were e
fractions. B) Ripoptosome recovery was carried out by immunoprecipitati
was performed on the Etoposide (Eto.) sample as a technical control for th
was associated with caspase8, while this was less evident in the empty ve
caspase8 in the empty vector population, as opposite to the ZFP36 and E
panel. C, D) Image J software provided a relative quantification of the leveamount of RIP1 bound to caspase-8 was strongly reduced
(Figure 2C) concomitantly to increased association between
caspase-8 and FADD (Figure 2D). This suggests that ZFP36
determines, by stabilizing RIP1, the aggregation of a com-
plex which, according to published data [11, 16, 17], might
unbalance cells towards necroptosis rather than apoptosis.
Therefore, we conclude that ZFP36 controls RIP1 stability,
promotes its assembly in a high molecular weight complex
and enhances its association to caspase-8 and FADD.plex containing caspase8 and FADD. A, B) Following 24 hours of
4 hours in the presence of 20 μM Z-VAD-FMK, in order to block
bed in Tenev et al. [8]. A positive control for Ripoptosome assembly
B, where HEK293T were treated for 24 hours with 100 μM Etoposide
r (E.V.) or ZFP36 transfected cells (ZFP36) were loaded on a Sepharose
olyacrylamide gel to perform Western blotting. In the presence of
hile this was less evident in E.V. samples. A positive control for RIP1
luted through the Sepharose column in order to identify the 2MDa
ng caspase8, while immunoprecipitation with nonspecific mouse IgG
e procedure. Both in the presence of ZFP36 or Etoposide (Eto.) RIP1
ctor population (E.V.). Higher levels of FADD were associated to
toposide (Eto.) samples. Input controls are represented on the right
ls of RIP1 and FADD associated to caspase8.
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stem cell lines
To test the relevance of our data, we assessed the ability of
ZFP36 to control RIP1 stability in human glioma neural
stem cell lines (GNS), as this population shows resistance
to standard therapy and is believed to mediate tumor
recurrence [13]. A panel of six different glioblastoma-
derived GNS cell lines were screened for ZFP36 expres-
sion, which resulted to be very heterogeneous (data not
shown). G144 GNS [18] express both ZFP36 and RIP1
when cultured in proliferation medium, and we detected a
reduction in the total RIP1 levels (Figure 3) upon deple-
tion of ZFP36, thus demonstrating that ZFP36 controls
RIP1 stability in this cancer stem cell context.
Discussion
RIP1 is a cytosolic molecule capable of mediating either
NF-kB signalling in resting conditions or necroptotic
and apoptotic cell death in response to stress [19]. The
regulation of RIP1 activity is dependent on the IAP E3
ubiquitine ligases cIAP-1, cIAP-2 and XIAP, which con-
stitutively ubiquitinate RIP1 in transformed cells, where
K63 ubiquitination promotes the assembly of a pro-
survival complex [19], while K48 might mediate RIP1
proteasomal degradation [8]. Anticancer drugs such as
Etoposide and SMAC-mimetics induce loss of IAPs and
promote Ripoptosome assembly, while some natural
molecules such as Interferons, are able to promoteFigure 3 ZFP36 controls RIP1 stability in glioma neural stem cells. Human
medium and transduced with a short hairpin lentivirus directed against ZF
sorted based on eGFP-positivity. Western blot analysis suggests that RIP1 st
to G144 that retain ZFP36 expression (pGIPZ).RIP1-dependent necroptosis [11]. A recent report dem-
onstrated that Etoposide induces ZFP36 expression [20]
and, moreover, it is interesting to note that ZFP36 levels
rise in response to the “breast cancer susceptibility pro-
tein” BRCA1 [21], which is implicated in the DNA dam-
age response. Even though Interferons induce ZFP36
expression [22], it is still unknown whether ZFP36 is
involved in mediating necroptosis in this setting.
Our data show that the ZFP36 mRNA binding protein
regulates negatively the stability of XIAP in glioma cancer
cells [4] and here we demonstrate in HEK293T cells that
ZFP36-dependent destabilization of cIAP2 and XIAP leads
to an increase in RIP1 levels and favors RIP1 association to
caspase-8 and FADD, while inducing cell death. These ob-
servations are consistent with described NF-kB inhibitory
activity of ZFP36 [23] and with reports of synergism be-
tween ZFP36 and TNF alpha in inducing cell death in
HEK293 cells [6]. Since our approach relies on ZFP36 res-
toration through transfection and is dependent on E3
ubiquitine ligases depletion, we identify the described mo-
lecular complex as the Ripoptosome. However, we cannot
exclude that ZFP36 could mediate the association of RIP1,
caspase-8 and FADD also in response to death receptor
signaling, as ZFP36 is induced and post-translationally reg-
ulated in response to TNF receptor activation [24, 25].
The observed control of ZFP36 over RIP1 stability in
GNS cell lines further supports the molecular mechan-
ism here described and suggests that GNS cell linesG144 glioma neural stem cells were grown in adhesion in proliferation
P36 (shZFP36) or with a scrambled short hairpin sequence (pGIPZ) and
ability is reduced in the absence of ZFP36 (shZFP36) when compared
Selmi et al. BMC Cancer  (2015) 15:357 Page 7 of 7that loose ZFP36 expression may be less sensitive to
necroptotic-inducing treatments. Taken together, our
results demonstrate a novel role for ZFP36 in regulating
Ripoptosome assembly and RIP1-dependent necroptosis
through IAP depletion.
Additional file
Additional file 1: ZFP36 controls RIP1 stability by regulating IAPs.
The expression of ZFP36 in HEK293 (pRRL-ZFP36) with a lentiviral vector
increases the levels of RIP1, when compared to the empty pRRL vector
(pRRL). This effect is restrained by the co-transfection of a XIAP expression
construct depleted of its own 3′UTR (pRRL-ZFP36 + D 3′UTR XIAP).
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